High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. (scientific article published in February 2007)

The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms

Q24681048

APACHE II: a severity of disease classification system

Q29547729

Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control

Q30652896

Aspergillosis case-fatality rate: systematic review of the literature

Q31918085

The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation

Q33364468

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis

Q33805542

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice

Q33806127

Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus

Q33857685

Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole

Q34125983

Caspofungin

Q34199905

Infectious morbidity in critically ill patients with cancer

Q34348047

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Q34455633

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

Q34553509

In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus

Q36492208

Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections

Q36568458

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

Q39652561

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Q39652771

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Q39652915

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations

Q39954432

Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.

Q40479359

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma

Q40622190

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis

Q40667866

Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Q42286250

Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis

Q42675899

The significance of blood cultures positive for emerging saprophytic moulds in cancer patients

Q43708608

Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifunga

Q44282959

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

Q44304226

Dematiaceous fungi are an increasing cause of human disease

Q44351397

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

Q44519647

Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy

Q44711161

Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery

Q44827799

Fusarium infection in hematopoietic stem cell transplant recipients

Q44883924

Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001).

Q44908393

Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis

Q44925292

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases

Q45015455

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

Q45066131

Combination antifungal therapy for invasive aspergillosis

Q45096994

Combination therapy for invasive aspergillosis

Q45096996

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

Q45172488

Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome

Q45198277

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

Q46393828

Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.

Q46592144

Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections

Q46861535

Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.

Q51189168

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

157-164

P577

publication date

2007-02-01

P1433

published in

Bone Marrow Transplantation

Q4941523

P1476

title

High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation.

P478

volume

Reverse relations

cites work (P2860)

Q39987609	Aspergillosis in hematopoietic stem cell transplant recipients: risk factors, prophylaxis, and treatment
Q41904981	Autophagy and Reactive Oxygen Species Are Involved in Neutrophil Extracellular Traps Release Induced by C. albicans Morphotypes.
Q37081683	Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients
Q28383437	Clinical implications of interferon-γ genetic and epigenetic variants
Q38806932	Combination therapy for the treatment of pulmonary mold infections
Q36924037	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
Q37779496	Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort
Q90577176	Extrapolating Antifungal Animal Data to Humans - Is it reliable?
Q39230127	Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia
Q51731561	Fungal cytoskeleton dysfunction or immune activation triggered by beta-glucan synthase inhibitors: potential mechanisms for the prolonged antifungal activity of echinocandins.
Q34415324	Fungal infection of the colon
Q38173720	High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events
Q86594429	Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation
Q46293266	In vitro activity of micafungin against biofilms of Candida albicans, Candida glabrata, and Candida parapsilosis at different stages of maturation
Q43680541	Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry?
Q37612914	Low Caspofungin Exposure in Patients in Intensive Care Units.
Q93200993	Paradoxical growth effect of caspofungin on Candida spp. sessile cells not only at high drug concentrations
Q40691888	Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Q38942828	Potential Microbiological Effects of Higher Dosing of Echinocandins.
Q49679966	Recent Insights into the Paradoxical Effect of Echinocandins
Q84637564	Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants